Literature DB >> 25696664

The metabolic syndrome - background and treatment.

P A van Zwieten.   

Abstract

The metabolic syndrome (MBS) is characterised by a clustering of cardiovascular and metabolic risk factors. This syndrome is now widely recognised as a distinct pathological entity, and it is receiving a great deal of attention in the medical literature but also in the lay press. Globally speaking, persons with MBS have a clustering of the following risk factors: [List: see text] MBS is associated with important cardio/cerebrovascular and metabolic risks. Prevention and treatment are therefore of great importance. Preventive measures involving lifestyle are mandatory. In addition, MBS patients require pharmacological treatment, usually for the rest of their lives. Complex patterns of drug treatment will be required, since all the different, heterogenous pathophysiological problems will require appropriate treatment. After an introduction to MBS, this article provides an extensive and critical review of the drug treatment of this complex pathological entity.

Entities:  

Keywords:  antihypertensive drugs; insulin resistance; metabolic syndrome; obesity; sympathetic activity

Year:  2006        PMID: 25696664      PMCID: PMC2557292     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  22 in total

Review 1.  A major health hazard: the metabolic syndrome.

Authors:  Bo Isomaa
Journal:  Life Sci       Date:  2003-09-26       Impact factor: 5.037

Review 2.  Obesity-associated hypertension: new insights into mechanisms.

Authors:  Kamal Rahmouni; Marcelo L G Correia; William G Haynes; Allyn L Mark
Journal:  Hypertension       Date:  2004-12-06       Impact factor: 10.190

3.  Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives.

Authors:  Guido Grassi; Raffaella Dell'Oro; Annalisa Facchini; Fosca Quarti Trevano; Giovanni Battista Bolla; Giuseppe Mancia
Journal:  J Hypertens       Date:  2004-12       Impact factor: 4.844

4.  The endocannabinoid system: a new therapeutic target for multi-risk factor management: Munich, 30 August 2004.

Authors:  L J Meijboom
Journal:  Neth Heart J       Date:  2004-11       Impact factor: 2.380

5.  Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population.

Authors:  K Masuo; H Mikami; T Ogihara; M L Tuck
Journal:  Am J Hypertens       Date:  1997-01       Impact factor: 2.689

6.  Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults.

Authors:  Shaista Malik; Nathan D Wong; Stanley S Franklin; Tripthi V Kamath; Gilbert J L'Italien; Jose R Pio; G Rhys Williams
Journal:  Circulation       Date:  2004-08-23       Impact factor: 29.690

7.  Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.

Authors:  Michael Schupp; Jürgen Janke; Ronald Clasen; Thomas Unger; Ulrich Kintscher
Journal:  Circulation       Date:  2004-04-26       Impact factor: 29.690

8.  Increased norepinephrine spillover into the jugular veins in essential hypertension.

Authors:  C Ferrier; M D Esler; G Eisenhofer; B G Wallin; M Horne; H S Cox; G Lambert; G L Jennings
Journal:  Hypertension       Date:  1992-01       Impact factor: 10.190

9.  Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women.

Authors:  Gang Hu; Qing Qiao; Jaakko Tuomilehto; Beverley Balkau; Knut Borch-Johnsen; Kalevi Pyorala
Journal:  Arch Intern Med       Date:  2004-05-24

10.  Metabolic syndrome and target organ damage in untreated essential hypertensives.

Authors:  Cesare Cuspidi; Stefano Meani; Veronica Fusi; Barbara Severgnini; Cristiana Valerio; Eleonora Catini; Gastone Leonetti; Fabio Magrini; Alberto Zanchetti
Journal:  J Hypertens       Date:  2004-10       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.